Novadip Biosciences is a biopharmaceutical company founded in 2013 by Pr D. Dufrane (UCL-IREC) and J.-F. Pollet on the basis of research performed within the Cliniques universitaires Saint-Luc - Centre de Thérapie Tissulaire et Cellulaire. This spin-off company aims to design, develop and bring to market innovative stem cell-based therapies for regenerative medicine.

Novadip: a key player for the world of tomorrow

Replace and repair large bone defects with stem cells from fatty tissue

The lead product Creost® introduces new principles of guided tissue regeneration based on stem cells from fatty tissue, associated with osteoinductive, osteoconductive and osteogenic properties, to manufacture 3D natural bone implants with the right shape, mineralisation and all mechanical properties for replacement and repair of large bone defects (spine surgery, orthopaedic surgery for trauma or tumour resection, cranial and maxillofacial surgery, osteonecrosis, etc.).

Next step: Process optimisation & industrialisation of Creost®, development of new products and preparation of next clinical trials

15 First-in-human clinical trials (hospital exemption) 2012-2015
Spin-off creation May 2013
2 Proofs of concept in severe bone reconstruction on pig models disorders 2011-2012
Research project beginning 2008